The Wall Street Journal has reported Thursday that generic drugmaker Impax Laboratories (NASDAQ:$IPXL) has entered talks with Amneal Pharmaceuticals (Privately Traded) about a possible merger.
IPXL is a pharmaceutical company specializing in developing, manufacturing and distributing generic drugs – also known as bioequivalent pharmaceutical products. The company focuses on creating generic versions of common drugs. They also create their own branded pharmaceutical product, Rytary, which is a carbidopa-levodopa extended-release oral capsule used in the treatment of Parkinson’s disease.
Back in March, it was reported that Impax had recruited Morgan Stanley (NYSE:$MS) to conduct a strategic overview of the company. IPXL has raised concern that about the current tough drug pricing environment.
IPXL currently boasts a Market Cap of $1.81 billion and a Beta 1.17. They have 74.31 million shares outstanding. The company last reported an EPS of -$8.08. They have a 52 week high of $27.29 and a 52 week low of $7.75.
Featured Image: twitter
